Table 3.
Survival of the 82 NPC patients with residual cervical lymphadenopathy
| Endpoint | Tumor cells in cervical lymph nodes | P value | Preoperative plasma EBV DNA | P value | ||
|---|---|---|---|---|---|---|
| Presence | Absence | Presence | Absence | |||
| Total (cases) | 68 | 14 | 36 | 46 | ||
| PFS | ||||||
| Failures [cases (%)] | 39 (57.4) | 2 (14.3) | 0.008 | 22 (61.1) | 19 (41.3) | 0.031 |
| 3-year rate [% (95% CI)] | 49.9 (37.6–62.2) | 83.3 (62.1–100) | 43.7 (26.1–61.3) | 61.1 (46.6–75.6) | ||
| OS | ||||||
| Deaths [cases (%)] | 21 (30.9) | 0 (0.0) | 0.014 | 13 (36.1) | 8 (17.4) | 0.020 |
| 3-year rate [% (95% CI)] | 83.2 (73.6–92.8) | 100 | 79.2 (64.3–94.1) | 90.7 (82.1–99.3) | ||
| DMFS | ||||||
| Failures [cases (%)] | 19 (27.9) | 1 (7.1) | 0.073 | 10 (27.8) | 10 (21.7) | 0.230 |
| 3-year rate [% (95% CI)] | 79.6 (69.2–90.0) | 91.7 (76.0–100) | 80.2 (65.9–94.5) | 85.9 (75.3–96.5) | ||
| LRRFS | ||||||
| Failures [cases (%)] | 33 (48.5) | 1 (7.1) | 0.005 | 20 (55.6) | 14 (30.4) | 0.009 |
| 3-year rate [% (95% CI)] | 53.9 (41.2–66.6) | 91.7 (76.0–100) | 46.4 (28.4–64.4) | 68.2 (53.7–82.7) | ||
| LRFS | ||||||
| Failures [cases (%)] | 19 (27.9) | 1 (7.1) | 0.102 | 13 (36.1) | 7 (15.2) | 0.017 |
| 3-year rate [% (95% CI)] | 71.0 (59.6–82.4) | 91.7 (76.0–100) | 61.1 (44.4–77.8) | 84.9 (73.7–96.1) | ||
| RRFS | ||||||
| Failures [cases (%)] | 21 (30.9) | 0 (0.0) | 0.014 | 13 (36.1) | 8 (17.4) | 0.027 |
| 3-year rate [% (95% CI)] | 73.0 (61.6–84.4) | 100 | 69.8 (52.9–86.7) | 80.7 (68.5–92.9) | ||
NPC nasopharyngeal carcinoma, PFS progression-free survival, OS overall survival, DMFS distant metastasis-free survival, LRRFS locoregional relapse-free survival, LRFS local relapse-free survival, RRFS regional relapse-free survival, CI confidence interval
P values were calculated with the unadjusted log-rank test